Catalent Inc (NASDAQ:CTLT) – Equities researchers at Jefferies Group raised their Q4 2017 earnings estimates for Catalent in a research note issued on Monday. Jefferies Group analyst D. Windley now expects that the firm will post earnings per share of $0.59 for the quarter, up from their prior forecast of $0.56. Jefferies Group currently has a “Hold” rating and a $28.00 price target on the stock.

A number of other equities analysts have also commented on CTLT. Morgan Stanley restated a “hold” rating on shares of Catalent in a research report on Tuesday, August 30th. Stephens began coverage on shares of Catalent in a research report on Tuesday, October 18th. They issued an “overweight” rating and a $31.00 price objective for the company. Zacks Investment Research upgraded shares of Catalent from a “strong sell” rating to a “hold” rating and set a $26.00 price objective for the company in a research report on Monday, October 31st. KeyCorp began coverage on shares of Catalent in a research report on Wednesday, October 19th. They issued an “overweight” rating and a $29.00 price objective for the company. Finally, TheStreet upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Wednesday, August 17th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. Catalent has an average rating of “Hold” and a consensus price target of $28.67.

Earnings History and Estimates for Catalent (NASDAQ:CTLT)

Shares of Catalent (NASDAQ:CTLT) traded up 0.04% during trading on Thursday, reaching $25.33. 733,422 shares of the company’s stock traded hands. The company has a market cap of $3.16 billion and a price-to-earnings ratio of 30.34. Catalent has a 52-week low of $18.92 and a 52-week high of $32.24. The company’s 50-day moving average is $24.48 and its 200 day moving average is $24.93.

Catalent (NASDAQ:CTLT) last released its quarterly earnings data on Monday, November 7th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.01. The company had revenue of $442.20 million for the quarter, compared to analyst estimates of $430.26 million. Catalent’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.18 earnings per share.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Commerce Bank increased its position in Catalent by 0.7% in the second quarter. Commerce Bank now owns 17,115 shares of the company’s stock valued at $393,000 after buying an additional 115 shares during the period. Forward Management LLC increased its position in Catalent by 1.5% in the third quarter. Forward Management LLC now owns 14,831 shares of the company’s stock valued at $383,000 after buying an additional 225 shares during the period. Profund Advisors LLC increased its position in Catalent by 1.2% in the third quarter. Profund Advisors LLC now owns 22,994 shares of the company’s stock valued at $594,000 after buying an additional 275 shares during the period. LS Investment Advisors LLC increased its position in Catalent by 5.2% in the third quarter. LS Investment Advisors LLC now owns 7,499 shares of the company’s stock valued at $194,000 after buying an additional 368 shares during the period. Finally, Bronfman E.L. Rothschild L.P. increased its position in Catalent by 7.6% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 5,673 shares of the company’s stock valued at $147,000 after buying an additional 400 shares during the period.

In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of Catalent stock in a transaction that occurred on Friday, September 9th. The shares were sold at an average price of $23.58, for a total transaction of $403,234,623.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

5 Day Chart for NASDAQ:CTLT

Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.